WHO "렘데시비르 코로나19 사망률 저감 효과 없어"

Remdesivir is known to be one of the most promising drugs used to treat COVID-19 patients.
But a new WHO study reportedly claims it doesn't help reduce mortality rates.
Kim Dami has the details.
The WHO says the antiviral medication remdesivir has no substantial effect on COVID-19 patients' chances of survival.
Developed by Gilead Sciences, remdesivir was among the first to be used as a COVID-19 treatment, known to be effective in shortening recovery time.
It was one of the drugs recently used during U.S. President Donald Trump's COVID-19 recovery process.
The UK-based Financial Times report cites results from the WHO's Solidarity trial, which evaluated the effects of four potential drugs on over 11-thousand hospitalized patients.
The drugs studied were remdesivir, hydroxychloroquine, anti-HIV combination drug of lopinavir/ritonavir and interferon.
Among them, hydroxychloroquine and lopinavir/ritonavir were already proven ineffective back in June.
In fact, based on the study, none of the four treatments substantially affected mortality rates or reduced the need to ventilate patients.
Earlier this month, Gilead Sciences said remdesivir shortened recovery time by five days compared to patients on placebo.
In South Korea, around 6-hundred COVID-19 patients at 62 hospitals have been treated with remdesivir.
The WHO is yet to comment on the Financial Times' report, saying the study's results have not yet been made public.
Kim Dami, Arirang News.